Harvoni

Deal Watch April 2016

In the last 4 years Gilead sales have grown from $8bn to $32bn (CAGR 40%), mainly driven by Sovaldi and Harvoni for hepatitis, resulting in a cash pile of over $20bn.

Gilead, Merck get CHMP backing for new hep C combinations

respectively. For Gilead, this is the first regulatory okay for Epclusa, a follow-up to its Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) products that currently dominate the HCV market with sales

Paywatch and the market access waters

Gilead's success with Sovaldi and Harvoni, whose total sales exceed $20bn, shows that a high price does not necessarily prevent market access.

AbbVie hepatitis C combo shows high cure rates

Gilead's main product is Harvoni (sofosbuvir/ledipasvir), which made around $10bn in sales last year, and also sells sofosbuvir as a single-agent product (as Sovaldi) that added another ... discount to both Harvoni and Viekirax.

Gilead must pay just $200m for hep C patents, says jury

Merck &Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni. ... Merck had been pushing for a 10% royalty rate on the $20.7bn Gilead had made from sales of two sofosbuvir-based drugs - Sovaldi and Harvoni - between 2013 and 2015, after

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]